Melbourne and Sydney (Australia) – 10 October 2018. Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularlytargeted radiation” (MTR), today announced that it has entered into a strategic collaboration agreement with GenesisCare Pty Ltd (“GenesisCare”), the largest private provider of oncology services in Australia and Europe.
The agreement covers three major collaboration areas. Firstly, GenesisCare and Telix have established a preferred clinical provider relationship for running radiation oncology studies in Australia for the inclusion of patients into Telix’s global multi-centre trials in neuro-oncology and urologic oncology. Secondly, GenesisCare and Telix will partner to deliver compassionate use access to Telix’s glioblastoma therapy program across its extensive patient network. Finally, Telix and GenesisCare will jointly explore the commercial potential of Telix’s products in China. Telix CEO Christian Behrenbruch stated, “GenesisCare is a unique organisation that has both patient access and geographic reach in radiation oncology. The kind of products that Telix is developing are a natural fit for the GenesisCare clinical network, both in terms of trials to support product development but also eventual product roll-out.” GenesisCare CEO Dan Collins commented, “We see strategic collaborations with companies like Telix as a way to advance clinical trials and make proven new treatments available more quickly – ultimately to improve life outcomes for patients. Healthcare access for all is also very important to us, and the compassionate-use program as part of this agreement will be life-changing for the patients involved. We look forward to a long partnership with Telix.”